More Weight Loss Drugs Are Coming, And They Could Be Even More Effective

Weight loss drugs are having a moment, owing to the fact that pharmaceutical companies have figured out how to help people lose up to double-digit percentages of their body weight and start dropping a more substantial number of pounds. Although Ozempic, Wegovy, and Rybelsus, all Novo Nordisk products, have dominated the market in the past year, Eli Lilly has its own pipeline of obesity medications. And new data the company revealed on June 23 suggest its products could give doctors and patients a greater range of options for treating the chronic condition—including more options in the form of pills, which could make them more accessible than the injectable types of medications that currently make up most of the weight-loss drug market. [time-brightcove not-tgx=”true”] At the annual meeting of the American Diabetes Association held in San Diego, Calif. from June 23 to June 26, Lilly presented results from studies of three of its weight loss drugs: tirzepatide (Mounjaro), orforglipron, and retatrutide. Tirzepatide, an injectable drug, targets two obesity-related hormones, glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP; orforglipron targets just GLP-1 but is a tablet so people can take it by mouth; and retatrutide, also an injectable therapy, targets three hormones, GLP-1, GIP, and glucagon. More from TIME [video id=tQEq3EOC autostart="viewable"] GLP-1-based drugs were originally developed to treat type 2 diabetes ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Drugs healthscienceclimate Source Type: news